BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.41.90//
CALSCALE:GREGORIAN
UID:63306430-6335-4634-b831-323239666365
BEGIN:VEVENT
UID:7c706a76e1c1b831d27c2c2a501a74eb190f8431@swoogo.com
DTSTAMP:20261012T163735Z
DESCRIPTION:Administering opioid agonist treatment is effective but resourc
 e-intensive\, leading to significant under-treatment of opioid dependence 
 in correctional settings worldwide. Researchers from Australia will discus
 s their study of long-acting injectable depot buprenorphine\, which showed
  treatment retention and outcomes comparable to those observed in communit
 y settings\, and to other opioid agonist treatment used in custodial setti
 ngs\, without increased risk of diversion. More than 2\,000 patients have 
 been initiated onto depot buprenorphine in New South Wales correctional fa
 cilities since January 2020.\n\nEducational Objectives:\n\n	* Cite the evid
 ence in support of opioid agonist treatment in correctional settings\n 	* D
 evelop clinical skills in prescribing depot buprenorphine\n 	* Examine oper
 ational\, structural\, and regulatory barriers to opioid agonist treatment
  in corrections\n\nLevel: Intermediate
DTSTART:20220802T153000Z
DTEND:20220802T163000Z
LAST-MODIFIED:20261012T163735Z
LOCATION:Capitol 5-7 Level 4
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:318 Lessons from Down Under: Implementing Depot Buprenorphine in Ne
 w South Wales
TRANSP:OPAQUE
X-ALT-DESC;FMTTYPE=text/html:<p>Administering opioid agonist treatment is e
 ffective but resource-intensive\, leading to significant under-treatment o
 f opioid dependence in correctional settings worldwide. Researchers from A
 ustralia will discuss their study of long-acting injectable depot buprenor
 phine\, which showed treatment retention and outcomes comparable to those 
 observed in community settings\, and to other opioid agonist treatment use
 d in custodial settings\, without increased risk of diversion. More than 2
 \,000 patients have been initiated onto depot buprenorphine in New South W
 ales correctional facilities since January 2020.</p>\n\n<p>Educational Obj
 ectives:</p>\n\n<ul><li>Cite the evidence in support of opioid agonist tre
 atment in correctional settings</li>\n	<li>Develop clinical skills in presc
 ribing depot buprenorphine</li>\n	<li>Examine operational\, structural\, an
 d regulatory barriers to opioid agonist treatment in corrections</li>\n</u
 l><p>Level: Intermediate</p>
BEGIN:VALARM
UID:31396362-3264-4533-a361-386633363566
ACTION:DISPLAY
DESCRIPTION:Administering opioid agonist treatment is effective but resourc
 e-intensive\, leading to significant under-treatment of opioid dependence 
 in correctional settings worldwide. Researchers from Australia will discus
 s their study of long-acting injectable depot buprenorphine\, which showed
  treatment retention and outcomes comparable to those observed in communit
 y settings\, and to other opioid agonist treatment used in custodial setti
 ngs\, without increased risk of diversion. More than 2\,000 patients have 
 been initiated onto depot buprenorphine in New South Wales correctional fa
 cilities since January 2020.\n\nEducational Objectives:\n\n	* Cite the evid
 ence in support of opioid agonist treatment in correctional settings\n 	* D
 evelop clinical skills in prescribing depot buprenorphine\n 	* Examine oper
 ational\, structural\, and regulatory barriers to opioid agonist treatment
  in corrections\n\nLevel: Intermediate
TRIGGER:-PT15M
END:VALARM
END:VEVENT
END:VCALENDAR